The company creates value by rescuing dormant assets from leading universities, developing and de-risking the technology through pre-clinical validation and licensing the IP to an industry partner.

Our aim is to transform innovative ideas into medical products as a means of expanding patient access to solutions that restore, repair or rebuild damaged tissue.